Your browser doesn't support javascript.
loading
Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial.
Xia, Shengli; Duan, Kai; Zhang, Yuntao; Zeng, Xiaoqing; Zhao, Dongyang; Zhang, Huajun; Xie, Zhiqiang; Li, Xinguo; Peng, Cheng; Zhang, Wei; Yang, Yunkai; Chen, Wei; Gao, Xiaoxiao; You, Wangyang; Wang, Xuewei; Wang, Zejun; Shi, Zhengli; Wang, Yanxia; Yang, Xuqin; Li, Qingliang; Huang, Lili; Wang, Qian; Lu, Jia; Yang, Yongli; Guo, Jing; Zhou, Wei; Wan, Xin; Wu, Cong; Wang, Wenhui; Huang, Shihe; Du, Jianhui; Nian, Xuanxuan; Deng, Tao; Yuan, Zhiming; Shen, Shuo; Guo, Wanshen; Liu, Jia; Yang, Xiaoming.
Afiliación
  • Xia S; Vaccine Clinical Research Center, Henan Center for Disease Control and Prevention, Zhengzhou, China.
  • Duan K; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China.
  • Zhang Y; Clinical Medical Center, China National Biotec Group Company Limited, Beijing, China.
  • Zeng X; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zhao D; Vaccine Clinical Research Center, Henan Center for Disease Control and Prevention, Zhengzhou, China.
  • Zhang H; Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  • Xie Z; Vaccine Clinical Research Center, Henan Center for Disease Control and Prevention, Zhengzhou, China.
  • Li X; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China.
  • Peng C; Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  • Zhang W; Vaccine Clinical Research Center, Henan Center for Disease Control and Prevention, Zhengzhou, China.
  • Yang Y; Clinical Medical Center, China National Biotec Group Company Limited, Beijing, China.
  • Chen W; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China.
  • Gao X; Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  • You W; Vaccine Clinical Research Center, Henan Center for Disease Control and Prevention, Zhengzhou, China.
  • Wang X; Clinical Medical Center, China National Biotec Group Company Limited, Beijing, China.
  • Wang Z; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China.
  • Shi Z; Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  • Wang Y; Vaccine Clinical Research Center, Henan Center for Disease Control and Prevention, Zhengzhou, China.
  • Yang X; Clinical Medical Center, China National Biotec Group Company Limited, Beijing, China.
  • Li Q; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China.
  • Huang L; Vaccine Clinical Research Center, Henan Center for Disease Control and Prevention, Zhengzhou, China.
  • Wang Q; Clinical Medical Center, China National Biotec Group Company Limited, Beijing, China.
  • Lu J; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China.
  • Yang Y; Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, China.
  • Guo J; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China.
  • Zhou W; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China.
  • Wan X; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China.
  • Wu C; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China.
  • Wang W; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China.
  • Huang S; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China.
  • Du J; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China.
  • Nian X; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China.
  • Deng T; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China.
  • Yuan Z; Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  • Shen S; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China.
  • Guo W; Vaccine Clinical Research Center, Henan Center for Disease Control and Prevention, Zhengzhou, China.
  • Liu J; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Yang X; National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, China.
Front Immunol ; 13: 898151, 2022.
Article en En | MEDLINE | ID: mdl-35812412
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Vacunas / COVID-19 Tipo de estudio: Clinical_trials Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Vacunas / COVID-19 Tipo de estudio: Clinical_trials Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article